The Benefits of Dual Inhibition of 5α Reductase

European Urology, Supplements

Volumn 5, Issue 20, 2006, Pages 1013-1017

  Djavan, Bob ^a   Mirone, Vincenzo ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

5 Reductase inhibitors; Benign prostatic hyperplasia; Dutasteride; Finasteride

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TYPE I 5ALPHA REDUCTASE INHIBITOR; TYPE II 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EJACULATION DISORDER; ENZYME INHIBITION; ENZYME REGULATION; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SEXUAL DYSFUNCTION; SYMPTOM;

EID: 33750532965     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.08.010     Document Type: Article

References (18)

1. Imperato-McGinley J. 5 alpha-reductase deficiency: human and animal models. Eur Urol 25 (1994) 20-23
2. Isaacs J.T. Antagonistic effect of androgen on prostatic cell death. Prostate 5 (1984) 545-557
3. Clark R.V., Hermann D.J., Cunningham G.R., Wilson T.H., Morrill B.B., and Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 89 (2004) 2179-2184
4. Bonkhoff H., Stein U., Aumuller G., and Remberger K. Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 29 (1996) 261-267
5. Lehlé C., Radvanyi F., Gil Diez de Medina S., et al. Differences in steroid 5 alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 68 (1999) 189-195
6. Bruchovsky N., Sadar M.D., Akakura K., Goldenberg S.L., Matsuoka K., and Rennie P.S. Characterization of 5 alpha-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol 59 (1996) 397-404
7. Silver R.I., Wiley E.L., Davis D.L., Thigpen A.E., Russell D.W., and McConnell J.D. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. J Urol 152 (1994) 433-437
8. Luo J., Dunn T.A., Ewing C.M., Walsh P.C., and Isaacs W.B. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma. Prostate 57 (2003) 134-139
9. Bartsch G., Muller H.R., Oberholzer M., and Rohr H.P. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 122 (1979) 487-491
10. Bramson H.N., Hermann D., Batchelor K.W., Lee F.W., James M.K., and Frye S.V. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 282 (1997) 1496-1502
11. Marks L.S., Partin A.W., Dorey F.J., et al. Long-term effects of finasteride on prostate tissue composition. Urology 53 (1999) 574-580
12. Roehrborn C., Andriole G., Schalken J., Wilson T., and Clark R. Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients. Eur Urol Suppl 2 (2003) 161 (abstract no. 635)
13. Debruyne F., Barkin J., van Erps P., et al. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488-495
14. Nickel J.C. Comparison of clinical trials with finasteride and dutasteride. Rev Urol 6 (2004) S31-S39
15. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., and Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
16. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338 (1998) 557-563
17. Andriole G.L., and Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44 (2003) 82-88
18. Hagerty J., Ginsberg P., and Harkaway R. A prospective, comparative study of the onset of symptomatic benefit of dutasteride versus finasteride in men with benign prostatic hyperplasia in everyday clinical practice. Eur Urol Suppl 3 2 (2004) 88 (abstract no. 343)